A Multicenter Randomized Open-Label Phase 3 Trial of Trastuzumab Deruxtecan(Enhertu�) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy PlusTrastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Participants withUnresectable Locally Advanced or Metastatic HER2-positive Gastric or GastroesophagealJunction (GEJ) Cancer (DESTINY-Gastric05)
